menu

Clinical Trials

HomeClinical DevelopmentClinical Trials
HomeClinical DevelopmentClinical Trials

Myrcludex B has been tested in a total of six clinical trials (four completed and two ongoing) that include 239 human subjects – healthy volunteers and Hepatitis B and D patients.

 

Study Description Results
MYR 101
Phase 1a
Germany
Safety study in healthy volunteers
(36 patients)
Excellent safety and tolerability
MYR 102
Phase 1
Germany
Drug interaction study in healthy volunteers
(12 patients)
No interaction detected
MYR 201
Phase 1b/2a
Russia NCT02881008
Study in Hepatitis B patients
(40 patients)
HBV DNA decline
ALT normalization
MYR 201
(HDV substudy)
Phase 1b/2a
Russia NCT02637999
Study in Hepatitis D patients
(16 patients plus comparison arm)

HDV RNA decline or negativation
ALT decrease

MYR 202
Phase 2
Germany, Russia
Study in Hepatitis D patients, on top of tenofovir (TDF) vs TDF
(120 patients)
HDV RNA decline or negativation in all dose groups
ALT decrease
Liver stiffness improvement
MYR 203
Phase 2
Russia (ongoing)
Study in Hepatitis D patients, on top of peg-Interferon (INF) vs INF Study in progress